Cell lines are still a tool of choice for many fields of biomedical research, including oncology.
Although cancer is a very complex disease, many discoveries have been made using …

Erythropoietin (EPO) is an evolutionarily conserved hormone well documented for its
erythropoietic role via binding the homodimeric EPO receptor (EPOR) 2. In past decades …

Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or
haematological malignancies, particularly in patients treated with chemotherapeutic agents …

Erythropoietin (EPO) is a glycoprotein cytokine known for its pleiotropic effects on various
types of cells and tissues. EPO and its receptor EPOR trigger signaling cascades …

Until 1990, erythropoietin (EPO) was considered to have a single biological purpose and
action, the stimulation of red blood cell growth and differentiation. Slowly, scientific and …

The increase in the life expectancy of patients with renal cell carcinoma (RCC) in the last
decade is due to changes that have occurred in the area of preclinical studies …

Introduction: Recombinant human erythropoietin (rhEPO) is a first-line therapeutic for the
anemia of chronic kidney disease, cancer chemotherapy, AIDS (Zidovudine therapy), and …

Ginsenoside Rg1 is one effective anticancer and antioxidant constituent of total saponins of
Panax ginseng (TSPG), which has been shown to have various pharmacological effects. Our …

Erythropoietin (Epo) is a pleiotropic cytokine, essential for erythropoiesis. Epo and its
receptor (Epo-R) are produced by several tissues and it is now admitted that Epo displays …

Background Several nomograms were developed for predicting the potential recurrence and
cancer death risk in renal cell carcinoma patients. The combination of TNM classification …